EzzElDien A. Ibrahim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
EzzElDien A. Ibrahim has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Hassan Ali
Division of Gastroenterology and Hepatology, University of Missouri School of Medicine, Columbia, Missouri, USA
2 shared publications - Akram Alnounou
Western Michigan University Homer Stryker MD School of Medicine
2 shared publications - Ghassan M. Hammoud
Division of Gastroenterology and Hepatology, University of Missouri School of Medicine, One Hospital Drive, DC043.00, Columbia, MO 65212, USA
2 shared publications - Mahmoud Mahdi
Division of Gastroenterology and Hepatology, University of Missouri School of Medicine, One Hospital Drive, DC043.00, Columbia, MO 65212, USA
2 shared publications - Mohammad Alabbas
Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, USA
2 shared publications - Aasma Shaukat
Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA
1 shared publication
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in JPGN Reports
Severe constipation‐associated postprandial abdominal pain in a pregnant native‐liver biliary atresia survivor after Kasai portoenterostomy: A case report
An 18‐year‐old woman with congenital biliary atresia status post Kasai portoenterostomy and magnetic resonance imaging‐reported chronic liver disease presented at 32 weeks’ gestation with 6 weeks of worsening postprandial epigastric/right upper quadrant pain, nausea, and poor oral intake. Evaluation showed preserved hepatic synthetic function and no demonstrated clinically significant portal hypertension. Endoscopy excluded esophageal and gastric varices, computed tomography showed no imaging evidence of pancreatitis, biliary obstruction, or other acute intra‐abdominal pathology, computed tomography angiography excluded mesenteric ischemia, and gastric emptying scintigraphy excluded gastroparesis. Nonreassuring fetal surveillance prompted preterm induction at approximately 33 weeks 4 days. Postpartum symptoms persisted, and imaging review identified severe constipation with rectal impaction/fecalization as the dominant treatable contributor. This case broadens the peripartum phenotype reported in native‐liver biliary atresia survivors by emphasizing constipation‐associated postprandial abdominal pain, poor oral intake, nutritional risk, and medication‐related bowel dysfunction rather than variceal bleeding or hepatic decompensation alone.
- 14 October 2026
- Published by Wiley in JPGN Reports
Open AccessSevere constipation‐associated postprandial abdominal pain in a pregnant native‐liver biliary atresia survivor after Kasai portoenterostomy: A case report
An 18‐year‐old woman with congenital biliary atresia status post Kasai portoenterostomy and magnetic resonance imaging‐reported chronic liver disease presented at 32 weeks’ gestation with 6 weeks of worsening postprandial epigastric/right upper quadrant pain, nausea, and poor oral intake. Evaluation showed preserved hepatic synthetic function and no demonstrated clinically significant portal hypertension. Endoscopy excluded esophageal and gastric varices, computed tomography showed no imaging evidence of pancreatitis, biliary obstruction, or other acute intra‐abdominal pathology, computed tomography angiography excluded mesenteric ischemia, and gastric emptying scintigraphy excluded gastroparesis. Nonreassuring fetal surveillance prompted preterm induction at approximately 33 weeks 4 days. Postpartum symptoms persisted, and imaging review identified severe constipation with rectal impaction/fecalization as the dominant treatable contributor. This case broadens the peripartum phenotype reported in native‐liver biliary atresia survivors by emphasizing constipation‐associated postprandial abdominal pain, poor oral intake, nutritional risk, and medication‐related bowel dysfunction rather than variceal bleeding or hepatic decompensation alone.
- 23 September 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- p. 1-11
Preexisting depression and early outcomes in inflammatory bowel disease: a propensity score–matched cohort study
Inflammatory bowel disease (IBD) is a chronic inflammatory condition with substantial cumulative morbidity, growing global burden, and considerable economic impact.1,2 Beyond intestinal pathology, ...
- 23 September 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- p. 1-11
Preexisting depression and early outcomes in inflammatory bowel disease: a propensity score–matched cohort study
Inflammatory bowel disease (IBD) is a chronic inflammatory condition with substantial cumulative morbidity, growing global burden, and considerable economic impact.1,2 Beyond intestinal pathology, ...
- 11 August 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (11) , 9653-9671
Early versus late direct endoscopic necrosectomy for pancreatic walled-off necrosis: a grade‑assessed systematic review with trial sequential evidence
- 11 August 2026
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (11) , 9653-9671
Early versus late direct endoscopic necrosectomy for pancreatic walled-off necrosis: a grade‑assessed systematic review with trial sequential evidence
- Open Access
Metabolic and Laboratory Biomarkers in Early-Onset Versus Late-Onset Colorectal Cancer: A Case–Control Study
Background: The incidence of early-onset colorectal cancer (EOCRC) is rising, yet the relative contribution of metabolic, inflammatory, and laboratory abnormalities remains incompletely defined. Objectives: We compared these associations between EOCRC and late-onset colorectal cancer (LOCRC) while addressing the possibility that some laboratory abnormalities may reflect occult cancer rather than antecedent risk. Methods: We conducted a matched case–control study using the TriNetX US Network. Adults diagnosed with CRC between 2010 and 2023 were identified as EOCRC (18–49 years) or LOCRC (50–75 years). Patients with prior malignancy, inflammatory bowel disease, hereditary or familial CRC risk, or prior colectomy were excluded. Three separate analyses were performed. First, a direct EOCRC-versus-LOCRC comparison evaluated gastrointestinal symptoms during the 6 months preceding diagnosis. Second, EOCRC and LOCRC were each compared with their respective matched cancer-free controls to assess clinical, metabolic, and laboratory features during the 24 months preceding diagnosis. When multiple laboratory values were available, the most recent value preceding the index date was used. Conditional logistic regression estimated adjusted odds ratios with 95% confidence intervals, with Bonferroni correction applied for multiple comparisons. Results: The direct matched EOCRC-versus-LOCRC comparison included 7752 patients with CRC, comprising 2584 with EOCRC and 5168 with LOCRC. EOCRC more frequently presented with rectal bleeding, abdominal pain, diarrhea, iron-deficiency anemia, and weight loss. Rectal tumors were more common in EOCRC, whereas proximal tumors were more common in LOCRC. In separate control-based analyses, 3217 patients with EOCRC and 12,112 patients with LOCRC were compared with 6434 and 24,336 matched cancer-free controls, respectively. The strongest independent features associated with EOCRC were severe obesity (aOR 2.61), microcytosis (aOR 2.29), low ferritin (aOR 2.11), and elevated C-reactive protein (aOR 1.87). Similar but generally attenuated associations were observed in LOCRC. In adjusted EOCRC-versus-LOCRC analyses, obesity (aOR 1.38), metabolic syndrome (aOR 1.41), and MASH (aOR 1.22) remained more closely associated with EOCRC. Conclusions: EOCRC is associated with a distinct clinical–metabolic phenotype, with more pronounced metabolic, inflammatory, and hematologic abnormalities than LOCRC. These findings should be interpreted as hypothesis-generating prediagnostic associations, not as validated predictors or causal risk factors.
Open AccessMetabolic and Laboratory Biomarkers in Early-Onset Versus Late-Onset Colorectal Cancer: A Case–Control Study
Background: The incidence of early-onset colorectal cancer (EOCRC) is rising, yet the relative contribution of metabolic, inflammatory, and laboratory abnormalities remains incompletely defined. Objectives: We compared these associations between EOCRC and late-onset colorectal cancer (LOCRC) while addressing the possibility that some laboratory abnormalities may reflect occult cancer rather than antecedent risk. Methods: We conducted a matched case–control study using the TriNetX US Network. Adults diagnosed with CRC between 2010 and 2023 were identified as EOCRC (18–49 years) or LOCRC (50–75 years). Patients with prior malignancy, inflammatory bowel disease, hereditary or familial CRC risk, or prior colectomy were excluded. Three separate analyses were performed. First, a direct EOCRC-versus-LOCRC comparison evaluated gastrointestinal symptoms during the 6 months preceding diagnosis. Second, EOCRC and LOCRC were each compared with their respective matched cancer-free controls to assess clinical, metabolic, and laboratory features during the 24 months preceding diagnosis. When multiple laboratory values were available, the most recent value preceding the index date was used. Conditional logistic regression estimated adjusted odds ratios with 95% confidence intervals, with Bonferroni correction applied for multiple comparisons. Results: The direct matched EOCRC-versus-LOCRC comparison included 7752 patients with CRC, comprising 2584 with EOCRC and 5168 with LOCRC. EOCRC more frequently presented with rectal bleeding, abdominal pain, diarrhea, iron-deficiency anemia, and weight loss. Rectal tumors were more common in EOCRC, whereas proximal tumors were more common in LOCRC. In separate control-based analyses, 3217 patients with EOCRC and 12,112 patients with LOCRC were compared with 6434 and 24,336 matched cancer-free controls, respectively. The strongest independent features associated with EOCRC were severe obesity (aOR 2.61), microcytosis (aOR 2.29), low ferritin (aOR 2.11), and elevated C-reactive protein (aOR 1.87). Similar but generally attenuated associations were observed in LOCRC. In adjusted EOCRC-versus-LOCRC analyses, obesity (aOR 1.38), metabolic syndrome (aOR 1.41), and MASH (aOR 1.22) remained more closely associated with EOCRC. Conclusions: EOCRC is associated with a distinct clinical–metabolic phenotype, with more pronounced metabolic, inflammatory, and hematologic abnormalities than LOCRC. These findings should be interpreted as hypothesis-generating prediagnostic associations, not as validated predictors or causal risk factors.
- Open Access
- 30 June 2026
- Published by MDPI AG in Therapeutics
- Vol. 3 (3) , 16
The Expansion of the Role of Endoscopic Ultrasound in the Field of Endohepatology
Background/Objective: Endohepatology has recently emerged as a field combining advanced endoscopy and hepatology. Endoscopic ultrasound (EUS) plays a key role in the management of patients with chronic liver disease. The main objective of this paper is to provide critical review on the recent advances in EUS-based liver diagnostics and therapeutics and how such advances have been central in establishing the field of Endohepatology. Methods: We searched the PubMed database for articles published since 1995 focused on the use of EUS in the field of Endohepatology. Our aim is to synthesize a narrative, non-systematic review emphasized on the evolving concepts, technical advancements, and clinical applications, particularly in areas where high-quality randomized data remain limited. Results: EUS-guided liver biopsy (EUS-LB) now offers diagnostic yield comparable to those of the percutaneous approaches. In addition, EUS-guided fine-needle biopsy (EUS-FNB) design and suction techniques have further optimized tissue sampling. Furthermore, EUS-guided portal pressure gradient (EUS-PPG) measurement is a promising alternative tool in risk stratification of patients with chronic advanced liver disease. EUS-based elastography enables real-time quantification of liver stiffness and fibrosis and evaluation of space-occupying lesions. Moreover, EUS-guided interventions can play important roles in the management of patients with portal hypertension-related bleeding. Finally, emerging applications include EUS-guided radiofrequency ablation (EUS-RFA), portal venous sampling, and intrahepatic shunt creation, which may further expand minimally invasive treatment options. Conclusions: State-of-the-art innovations expanded the role of EUS not only in diagnostics but also in the therapeutic role of EUS and provided a new paradigm for the care of patients with liver disease.
- 30 June 2026
- Published by MDPI AG in Therapeutics
- Vol. 3 (3) , 16
Open AccessThe Expansion of the Role of Endoscopic Ultrasound in the Field of Endohepatology
Background/Objective: Endohepatology has recently emerged as a field combining advanced endoscopy and hepatology. Endoscopic ultrasound (EUS) plays a key role in the management of patients with chronic liver disease. The main objective of this paper is to provide critical review on the recent advances in EUS-based liver diagnostics and therapeutics and how such advances have been central in establishing the field of Endohepatology. Methods: We searched the PubMed database for articles published since 1995 focused on the use of EUS in the field of Endohepatology. Our aim is to synthesize a narrative, non-systematic review emphasized on the evolving concepts, technical advancements, and clinical applications, particularly in areas where high-quality randomized data remain limited. Results: EUS-guided liver biopsy (EUS-LB) now offers diagnostic yield comparable to those of the percutaneous approaches. In addition, EUS-guided fine-needle biopsy (EUS-FNB) design and suction techniques have further optimized tissue sampling. Furthermore, EUS-guided portal pressure gradient (EUS-PPG) measurement is a promising alternative tool in risk stratification of patients with chronic advanced liver disease. EUS-based elastography enables real-time quantification of liver stiffness and fibrosis and evaluation of space-occupying lesions. Moreover, EUS-guided interventions can play important roles in the management of patients with portal hypertension-related bleeding. Finally, emerging applications include EUS-guided radiofrequency ablation (EUS-RFA), portal venous sampling, and intrahepatic shunt creation, which may further expand minimally invasive treatment options. Conclusions: State-of-the-art innovations expanded the role of EUS not only in diagnostics but also in the therapeutic role of EUS and provided a new paradigm for the care of patients with liver disease.
- Open Access
- 19 January 2026
- Published by MDPI AG in Preprints.org
The Expansion of the Role of Endoscopic Ultrasound in the Field of Endohepatology
Background/Objective: Endohepatology has recently emerged as a field combining advanced endoscopy and hepatology. Endoscopic ultrasound (EUS) plays a key role in the management of patients with chronic liver disease. The main objective of this paper is to provide critical review on the recent advances in EUS-based liver diagnostics and therapeutics and how such advances have been central in establishing the field of Endohepatology. Methods: We searched the PubMed database for articles published since 1995 focused on the use of EUS in the field of Endohepatology. Results: EUS-guided liver biopsy (EUS-LB) now offers diagnostic yield and therapeutic options comparable to those of the percutaneous and/or transjugular approaches. In addition, EUS-guided fine needle biopsy (EUS-FNB) design and suction techniques have further optimized tissue sampling. Further-more, EUS-guided portal pressure gradient (EUS-PPG) measurement is an alter-native to transjugular method. EUS-based elastography enables real-time quantification of liver stiffness and fibrosis and evaluation of space-occupying lesions. Moreover, EUS-guided interventions can play important roles in the management of patients with portal hypertension-related bleeding. Finally, emerging applications include EUS-guided radiofrequency ablation (EUS-RFA), portal venous sampling, and intrahepatic shunt creation, which may further expand minimally invasive treatment options. Conclusions: State-of-the-art innovations expanded the role of EUS not only in diagnostics, but also in the therapeutic role of EUS, and provided a new paradigm for the care of patients with liver disease.
- 19 January 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Expansion of the Role of Endoscopic Ultrasound in the Field of Endohepatology
Background/Objective: Endohepatology has recently emerged as a field combining advanced endoscopy and hepatology. Endoscopic ultrasound (EUS) plays a key role in the management of patients with chronic liver disease. The main objective of this paper is to provide critical review on the recent advances in EUS-based liver diagnostics and therapeutics and how such advances have been central in establishing the field of Endohepatology. Methods: We searched the PubMed database for articles published since 1995 focused on the use of EUS in the field of Endohepatology. Results: EUS-guided liver biopsy (EUS-LB) now offers diagnostic yield and therapeutic options comparable to those of the percutaneous and/or transjugular approaches. In addition, EUS-guided fine needle biopsy (EUS-FNB) design and suction techniques have further optimized tissue sampling. Further-more, EUS-guided portal pressure gradient (EUS-PPG) measurement is an alter-native to transjugular method. EUS-based elastography enables real-time quantification of liver stiffness and fibrosis and evaluation of space-occupying lesions. Moreover, EUS-guided interventions can play important roles in the management of patients with portal hypertension-related bleeding. Finally, emerging applications include EUS-guided radiofrequency ablation (EUS-RFA), portal venous sampling, and intrahepatic shunt creation, which may further expand minimally invasive treatment options. Conclusions: State-of-the-art innovations expanded the role of EUS not only in diagnostics, but also in the therapeutic role of EUS, and provided a new paradigm for the care of patients with liver disease.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1) , 7550224
Incident Cognitive Impairment in Nonobese Versus Obese Adults Aged 50 Years or Older With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Propensity Score–Matched Cohort Study
Aims: Nonobese metabolic dysfunction‐associated steatotic liver disease (MASLD) may carry disproportionate neurodegenerative risk, but whether body habitus modifies cognitive risk within MASLD remains unresolved. We compared cognitive impairment between nonobese and obese adults aged 50 years or older with MASLD. Methods and Results: Retrospective cohort study with 1:1 propensity score matching in the TriNetX Research Network, a federated electronic health record network. Adults with a first MASLD diagnosis (2016–2022) meeting a metabolic‐risk criterion were classified by index body mass index as nonobese (18.50–29.99 kg/m 2 ) or obese (≥ 30.00 kg/m 2 ); underweight patients were excluded. The primary outcome was a composite of incident cognitive impairment (mild cognitive impairment [MCI] through dementia) over Days 366–1825. Hazard ratios (HRs) were estimated with Kaplan–Meier and log‐rank methods; a negative control (acute appendicitis) and an E ‐value assessed bias. Matching yielded 36,021 patients per group (mean age 64.3 years; 57% women; all standardized mean differences < 0.10). Nonobese MASLD was associated with a higher risk of the composite cognitive outcome (2.9% vs 2.6%; HR 1.126, 95% confidence interval [CI] 1.031–1.230; p = 0.008; E ‐value 1.50), driven by MCI (HR 1.221, 95% CI 1.078–1.384; p = 0.002). Estimates were null for incident Alzheimer disease, all‐cause dementia, vascular dementia, all‐cause mortality, and the negative control. Conclusion: Among adults aged 50 years or older with MASLD, nonobese status was associated with a modestly higher risk of incident cognitive impairment. Prospective validation in imaging‐ or biomarker‐confirmed MASLD cohorts is warranted.
- 1 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1) , 7550224
Open AccessIncident Cognitive Impairment in Nonobese Versus Obese Adults Aged 50 Years or Older With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Propensity Score–Matched Cohort Study
Aims: Nonobese metabolic dysfunction‐associated steatotic liver disease (MASLD) may carry disproportionate neurodegenerative risk, but whether body habitus modifies cognitive risk within MASLD remains unresolved. We compared cognitive impairment between nonobese and obese adults aged 50 years or older with MASLD. Methods and Results: Retrospective cohort study with 1:1 propensity score matching in the TriNetX Research Network, a federated electronic health record network. Adults with a first MASLD diagnosis (2016–2022) meeting a metabolic‐risk criterion were classified by index body mass index as nonobese (18.50–29.99 kg/m 2 ) or obese (≥ 30.00 kg/m 2 ); underweight patients were excluded. The primary outcome was a composite of incident cognitive impairment (mild cognitive impairment [MCI] through dementia) over Days 366–1825. Hazard ratios (HRs) were estimated with Kaplan–Meier and log‐rank methods; a negative control (acute appendicitis) and an E ‐value assessed bias. Matching yielded 36,021 patients per group (mean age 64.3 years; 57% women; all standardized mean differences < 0.10). Nonobese MASLD was associated with a higher risk of the composite cognitive outcome (2.9% vs 2.6%; HR 1.126, 95% confidence interval [CI] 1.031–1.230; p = 0.008; E ‐value 1.50), driven by MCI (HR 1.221, 95% CI 1.078–1.384; p = 0.002). Estimates were null for incident Alzheimer disease, all‐cause dementia, vascular dementia, all‐cause mortality, and the negative control. Conclusion: Among adults aged 50 years or older with MASLD, nonobese status was associated with a modestly higher risk of incident cognitive impairment. Prospective validation in imaging‐ or biomarker‐confirmed MASLD cohorts is warranted.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1)
SGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence
Goal: The goal is to systematically evaluate the efficacy and safety of SGLT‐2 inhibitors (SGLT2i) versus standard therapy for ascites management in liver cirrhosis. Background: SGLT2i promote natriuresis and osmotic diuresis, offering potential therapeutic benefits for fluid overload in cirrhosis, similar to their established role in heart failure. However, high‐quality comparative evidence remains limited. Study: A systematic search of PubMed, Scopus, Cochrane, Embase, and Web of Science was conducted through October 2025 following PRISMA 2020 guidelines. Eligible studies included randomized controlled trials and prospective comparative studies enrolling adults (≥ 18 years) with confirmed cirrhosis treated with dapagliflozin or empagliflozin, alone or alongside standard therapy, versus placebo or standard care for ≥ 2 weeks. The primary outcome was complete ascites resolution; secondary outcomes included mortality, body weight, eGFR, and serum creatinine and sodium levels. Results: Three studies (two RCTs and one prospective trial; n = 382) were included, comprising 241 patients receiving SGLT2i and 141 controls. SGLT2i significantly increased complete ascites resolution (OR: 2.39, 95% CI: 1.47–3.90; p < 0.001; I 2 = 15 % ) and reduced body weight (MD: −4.86 kg, 95% CI: −7.57 to −2.14; p = 0.0005; I 2 = 0 % ). No significant differences were observed in eGFR, serum creatinine, serum sodium, or mortality within the RCT subgroup (OR: 1.60, 95% CI: 0.53–4.87; I 2 = 0 % ); the overall three‐study pool (OR: 0.27, 95% CI: 0.13–0.56; I 2 = 87 % ) was driven by the nonrandomized trial (test for subgroup differences p = 0.001). The only placebo‐controlled RCT reported significantly higher rates of AKI (50% vs. 15%, p = 0.04) and infections (55% vs. 20%, p = 0.04) in the SGLT2i arm. Conclusions: SGLT2i improved ascites resolution and body weight without changes in routinely measured renal parameters, but unresolved AKI and infection signals and very low GRADE certainty for mortality preclude routine clinical use. SGLT2i should be considered only as individualized investigational therapy under close monitoring pending larger RCTs. PROSPERO (CRD420261303781).
- 1 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1)
Open AccessSGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence
Goal: The goal is to systematically evaluate the efficacy and safety of SGLT‐2 inhibitors (SGLT2i) versus standard therapy for ascites management in liver cirrhosis. Background: SGLT2i promote natriuresis and osmotic diuresis, offering potential therapeutic benefits for fluid overload in cirrhosis, similar to their established role in heart failure. However, high‐quality comparative evidence remains limited. Study: A systematic search of PubMed, Scopus, Cochrane, Embase, and Web of Science was conducted through October 2025 following PRISMA 2020 guidelines. Eligible studies included randomized controlled trials and prospective comparative studies enrolling adults (≥ 18 years) with confirmed cirrhosis treated with dapagliflozin or empagliflozin, alone or alongside standard therapy, versus placebo or standard care for ≥ 2 weeks. The primary outcome was complete ascites resolution; secondary outcomes included mortality, body weight, eGFR, and serum creatinine and sodium levels. Results: Three studies (two RCTs and one prospective trial; n = 382) were included, comprising 241 patients receiving SGLT2i and 141 controls. SGLT2i significantly increased complete ascites resolution (OR: 2.39, 95% CI: 1.47–3.90; p < 0.001; I 2 = 15 % ) and reduced body weight (MD: −4.86 kg, 95% CI: −7.57 to −2.14; p = 0.0005; I 2 = 0 % ). No significant differences were observed in eGFR, serum creatinine, serum sodium, or mortality within the RCT subgroup (OR: 1.60, 95% CI: 0.53–4.87; I 2 = 0 % ); the overall three‐study pool (OR: 0.27, 95% CI: 0.13–0.56; I 2 = 87 % ) was driven by the nonrandomized trial (test for subgroup differences p = 0.001). The only placebo‐controlled RCT reported significantly higher rates of AKI (50% vs. 15%, p = 0.04) and infections (55% vs. 20%, p = 0.04) in the SGLT2i arm. Conclusions: SGLT2i improved ascites resolution and body weight without changes in routinely measured renal parameters, but unresolved AKI and infection signals and very low GRADE certainty for mortality preclude routine clinical use. SGLT2i should be considered only as individualized investigational therapy under close monitoring pending larger RCTs. PROSPERO (CRD420261303781).